In breast cancer, nobiletin has been found to significantly inhibit the protein tyrosine kinase 2 (PTK2)/SRC/STAT3 angiogenetic signaling pathway, and, consequently, tumor proliferation (Sp et al., 2017). This evidence concerns the gene PTK2 and breast carcinoma.